Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a $45 price target.
April 12, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on PTC Therapeutics and maintained a $45 price target.
The reiteration of an Overweight rating and the maintenance of a $45 price target by a reputable analyst could signal confidence in PTC Therapeutics' fundamentals and future prospects. This endorsement may positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100